DCE-MR imaging of orbital lesions: diagnostic performance of the tumor flow residence time τ calculated by a multi-compartmental pharmacokinetic tumor model based on individual factors

Abstract

Background

Differentiating benign from malignant orbital lesions by imaging and clinical presentation can be challenging.

Purpose

To differentiate benign from malignant orbital masses using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) based on tumor flow residence time τ calculated with the aid of a pharmacokinetic tumor model.

Material and Methods

Sixty patients with orbital masses were investigated by 3-T MRI including dynamic sequences. The signal intensity-time curve after i.v. contrast medium administration within lesions was approximated by Gd-concentration profiles on the basis of model calculations where the tumor is embedded in a whole-body kinetic model. One output of the model was tumor flow residence time τ, defined as the ratio of the tumor volume and the tumor blood flow rate. Receiver operating characteristic (ROC) curves were used to analyze the diagnostic performance of τ. The results were compared with those of K^trans, k_ep, v_e, iAUC, and ADC.

Results

Thirty-one benign and 29 malignant orbital masses were identified (reference standard: histopathology, clinical characteristics). Mean τ was significantly longer for benign masses (94 ± 48 s) than for malignant masses (21 ± 19 s, P < 0.001). ROC analysis revealed the highest area under the curve (AUC = 0.94) for τ in orbital masses compared to standard methods.

Conclusion

Tumor flow residence times τ of benign and malignant orbital masses are valuable in the diagnostic work-up of orbital tumors. Measures of diagnostic accuracy were superior for τ compared to ADC, K^trans, v_e, and iAUC.

Keywords

Head/neck magnetic resonance diffusion/perfusion orbit contrast agents – intravenous tissue characterization

Get full access to this article

View all access options for this article.

References

Tailor

Gupta

Dalley

et al . Orbital neoplasms in adults: clinical, radiologic, and pathologic review. Radiographics 2013; 33:1739–1758.

Ben Simon

Annunziata

Fink

et al . Rethinking orbital imaging establishing guidelines for interpreting orbital imaging studies and evaluating their predictive value in patients with orbital tumors. Ophthalmology 2005; 112:2196–2207.

Politi

Forghani

Godi

et al . Ocular adnexal lymphoma: diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring. Radiology 2010; 256:565–574.

Sepahdari

Politi

Aakalu

et al . Diffusion-weighted imaging of orbital masses: multi-institutional data support a 2-ADC threshold model to categorize lesions as benign, malignant, or indeterminate. Am J Neuroradiol 2014; 35:170–175.

Oostendorp

Post

Backes

WH.

Vessel growth and function: depiction with contrast-enhanced MR imaging.

Radiology 2009; 251:317–335.

Folkman

Tumor angiogenesis: therapeutic implications.

N Engl J Med 1971; 285:1182–1186.

Kuhl

Mielcareck

Klaschik

et al . Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211:101–110.

Yamamoto

Han

Kim

et al . Breast cancer: radiogenomic biomarker reveals associations among dynamic contrast-enhanced MR imaging, long noncoding RNA, and metastasis. Radiology 2015; 275:384–392.

Huang

Tudorica

et al . Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging. Radiology 2011; 261:394–403.

10.

Tofts

Kermode

AG.

Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts.

Magn Reson Med 1991; 17:357–367.

11.

Brix

Semmler

Port

et al . Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991; 15:621–628.

12.

Lawaczeck R, Jost G, Pietsch H. Pharmacokinetics of contrast media in humans: model with circulation, distribution, and renal excretion. Invest Radiol 2011;46:576–85.

13.

13. Renz DM, Diekmann F, Schmitzberger FF, et al. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time. Invest Radiol 2013;48:69–78.

14.

Brix

Kiessling

Lucht

et al . Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn Reson Med 2004; 52:420–429.

15.

Pathak

Artemov

Ward

et al . Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res 2005; 65:1425–1432.

16.

Feng

Jeong

Mohs

et al . Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice. Magn Reson Med 2008; 60:1347–1352.

17.

Pitterich

Lawaczeck

On the water and proton permeabilities across membranes from erythrocyte ghosts.

Biochim Biophys Acta 1985; 821:233–242.

18.

Violon

Kinetics of intravenous radiographic contrast medium injections as used on CT: simulation with time delay differential equations in a basic human cardiovascular multicompartment model.

Br J Radiol 2012; 85:e1212–1218.

19.

Tofts

PS.

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

J Magn Reson Imaging 1997; 7:91–101.

20.

Tofts

Brix

Buckley

et al . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10:223–232.

21.

Yuan

Kuai

Chen

et al . Assessment of dynamic contrast-enhanced magnetic resonance imaging in the differentiation of malignant from benign orbital masses. Eur J Radiol 2013; 82:1506–1511.

22.

Xian

Zhang

Wang

et al . Value of MR imaging in the differentiation of benign and malignant orbital tumors in adults. EurRadiol 2010; 20:1692–1702.

23.

Sepahdari

Aakalu

Setabutr

et al . Indeterminate orbital masses: restricted diffusion at MR imaging with echo-planar diffusion-weighted imaging predicts malignancy. Radiology 2010; 256:554–564.

24.

Razek

Elkhamary

Mousa

Differentiation between benign and malignant orbital tumors at 3-T diffusion MR-imaging.

Neuroradiology 2011; 53:517–522.

25.

Fatima

Ichikawa

Ishigame

et al . Orbital masses: the usefulness of diffusion-weighted imaging in lesion categorization. Clin Neuroradiol 2014; 24:129–134.

26.

Zhang

Sha

Qian

et al . Role of magnetic resonance diffusion-weighted imaging in differentiating lacrimal masses. J Magn Reson Imaging 2014; 40:641–648.

27.

Kapur

Sepahdari

Mafee

et al . MR imaging of orbital inflammatory syndrome, orbital cellulitis, and orbital lymphoid lesions: the role of diffusion-weighted imaging. Am J Neuroradiol 2009; 30:64–70.

28.

Sepahdari

Aakalu

Kapur

et al . MRI of orbital cellulitis and orbital abscess: the role of diffusion-weighted imaging Am J Roentgenol 2009; 193:W244–250.

29.

Ro SR, Asbach P, Siebert E, et al. Characterization of orbital masses by multiparametric MRI. Eur J Radiol 2016;85:324–36.

30.

Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1.

Arch Ophthalmol 1990; 108:1268–1273.

31.

Vaupel

Pathophysiology of solid tumors. Berlin: Springer-Verlag Berlin Heidelberg, 2009.